Cell Signaling Technology is proud to partner with the Koch Institute at MIT, Science, and Science Signaling to present the Targeting Cancer Pathways webinar series. These webinars bring together thought leaders from around the world to share current findings and further cancer research community collaboration.

This two part webinar features Dr. Li Huei Tsai from the Picower Institute at MIT and CST Development Scientist, Dr. Raphael Rozenfeld. Dr. Tsai discusses how modeling systems can be combined with immunolabeling and imaging techniques to unlock the mystery of Alzheimer's Disease. Dr Rozenfeld describes the rigorous validation procedure our antibodies undergo before being release, with special emphasis placed on our neuroscience portfolio. Check out the abstracts below and then click on the button to watch their exciting presentations.

Cell Signaling Technology is proud to present the following On-Demand Webinar: 

The Use of Highly Validated Antibodies and Optimized ChIP Assays to Analyze Epigenetic Marks and Mechanism in DIsease

Sayura Aoyagi, Ph.D, CST Antibody Validation Scientist

Lack of reproducibility in scientific studies has been a major topic of conversation lately. It's an important conversation for us to have, given the potential of this problem to affect how the research community views the published literature.  Many potential reasons for the problem exist, but CST is focused on the role vendors play in ensuring the reagents being used by the scientific community are properly validated. 

These are important issues that need to be addressed by the scientific community and we should all be part of the conversation . . . 

This is part two of a two-part series on how to optimize your IHC protocols. Part one introduced the principles behind antigen retrival. Click here if you missed it... but, if you've got your tissue prepped and ready to go, we'll move on to the next steps in the staining protocol.

It’s Friday night and you could be out with your friends right now, but instead you’re tucked away in a dark little room filled with microscopes. Spending the evening in the lab seemed like a good choice at the time because you were certain this immunohistochemistry was going to reveal some small - but important - mystery of the universe to you. But now you’re sitting here, cursing the universe and everyone in it, because all you see when you stare down into the scope is some indistinct fuzziness. And did the controls work - meh - who’s to say? There’s no sugar coating it. It’s a fail.

Immune cells divide rapidly when mounting an immune response against a pathogen, for example, or when initiating a wound-healing response. To accommodate the increased energy requirements to mount the immune response, these cells may employ metabolic pathways similar to those engaged by cancer cells—pathways such as aerobic glycolysis. This correlation presents the intriguing possibility that understanding immune cell metabolism will provide new and actionable insights into the behavior of tumor cells. In this webinar, our expert speakers will explore how this phenomenon is being studied and describe how it could enable the development of new strategies in the fight against cancer. 

See a real life example of how PTMScan technology can facilitate translational discovery. In this short video we describe how CST not only identified a major driver of NSCLC, which can respond to an FDA approved drug, but went a step further and developed an antibody that can be used to test which patients might be candidates for treatment. All thanks to the power of simplified proteomics.

Antibodies targeted to histone modifications may bind non-specifically to similar, but off-target histone modifications. Conversely, their specific binding can be inhibited by steric hindrance from modifications on neighboring residues. Assays like ELISA, western blot, ChIP, and IF are commonly used to demonstrate antibody specificity and sensitivity, but they cannot clearly predict how an antibody will interact with nearby epitopes. As a result, an alternative approach is needed when trying to validate an antibody to a histone modification target. Continue reading to see how we do it.

Whether your lab is well-versed and equipped to do Mass Spec analysis in-house or your lab has never considered setting up a proteomics experiment before, the Proteomics group at CST has a solution to help clear the way.  Click below to watch the video and learn more.